002370 亚太药业
已收盘 09-08 15:00:00
资讯
新帖
简况
亚太药业(002370)6月30日股东户数6.8万户，较上期减少22.86%
证券之星 · 08-26
亚太药业(002370)6月30日股东户数6.8万户，较上期减少22.86%
亚太药业2026年半年报：扣非净利扭亏，经营现金流转负
蓝鲸财经 · 08-26
亚太药业2026年半年报：扣非净利扭亏，经营现金流转负
图解亚太药业中报：第二季度单季净利润同比下降98.10%
证券之星 · 08-26
图解亚太药业中报：第二季度单季净利润同比下降98.10%
亚太药业扣非净利润同比增长102.86% 多维布局积蓄新动能
中国财富通 · 08-25
亚太药业扣非净利润同比增长102.86% 多维布局积蓄新动能
股市必读：亚太药业新发布《关于与专业投资机构共同投资的进展公告》
证券之星 · 08-21
股市必读：亚太药业新发布《关于与专业投资机构共同投资的进展公告》
股市必读：亚太药业新发布《关于与专业投资机构共同投资的进展公告》
证券之星 · 08-20
股市必读：亚太药业新发布《关于与专业投资机构共同投资的进展公告》
股市必读：亚太药业新发布《关于全资子公司参与认购投资基金份额的公告》
证券之星 · 08-13
股市必读：亚太药业新发布《关于全资子公司参与认购投资基金份额的公告》
亚太药业（002370）披露全资子公司参与认购投资基金份额公告，8月11日股价上涨0.86%
证券之星 · 08-11
亚太药业（002370）披露全资子公司参与认购投资基金份额公告，8月11日股价上涨0.86%
亚太药业：首次回购公司股份3344500股
证券日报网 · 08-11
亚太药业：首次回购公司股份3344500股
异动快报：亚太药业（002370）8月10日9点38分触及涨停板
证券之星 · 08-10
异动快报：亚太药业（002370）8月10日9点38分触及涨停板
股市必读：亚太药业新发布《关于回购公司股份的进展公告》
证券之星 · 08-06
股市必读：亚太药业新发布《关于回购公司股份的进展公告》
亚太药业（002370）披露回购公司股份进展公告，8月4日股价上涨2.43%
证券之星 · 08-04
亚太药业（002370）披露回购公司股份进展公告，8月4日股价上涨2.43%
亚太药业：截至2025年末，在职员工人数较2024年末减少18人
证券之星 · 08-04
亚太药业：截至2025年末，在职员工人数较2024年末减少18人
亚太药业（002370）披露螺内酯片通过仿制药一致性评价公告，8月3日股价上涨1.65%
证券之星 · 08-03
亚太药业（002370）披露螺内酯片通过仿制药一致性评价公告，8月3日股价上涨1.65%
股市必读：亚太药业新发布《关于回购股份事项前十名股东和前十名无限售条件股东持股情况的公告》
证券之星 · 08-03
股市必读：亚太药业新发布《关于回购股份事项前十名股东和前十名无限售条件股东持股情况的公告》
亚太药业（002370）披露回购股份事项前十名股东持股情况公告，7月31日股价上涨1.68%
证券之星 · 07-31
亚太药业（002370）披露回购股份事项前十名股东持股情况公告，7月31日股价上涨1.68%
亚太药业(002370.SZ)：螺内酯片通过仿制药质量和疗效一致性评价
智通财经 · 07-31
亚太药业(002370.SZ)：螺内酯片通过仿制药质量和疗效一致性评价
股市必读：亚太药业（002370）新发布《关于取得金融机构股票回购专项贷款承诺函的公告》
证券之星 · 07-31
股市必读：亚太药业（002370）新发布《关于取得金融机构股票回购专项贷款承诺函的公告》
亚太药业（002370）披露取得金融机构股票回购专项贷款承诺函的公告，7月29日股价下跌0.21%
证券之星 · 07-29
亚太药业（002370）披露取得金融机构股票回购专项贷款承诺函的公告，7月29日股价下跌0.21%
亚太药业最新公告：拟以1000万元至2000万元回购公司股份
证券之星 · 07-29
亚太药业最新公告：拟以1000万元至2000万元回购公司股份
加载更多
公司概况
公司名称：
浙江亚太药业股份有限公司
所属行业：
医药制造业
上市日期：
2010-03-16
主营业务：
浙江亚太药业股份有限公司的主营业务是医药制造业务，包括化学制剂的研发、生产和销售。公司的主要产品是抗生素类制剂、非抗生素类制剂。公司拥有省级企业技术中心。
发行价格：
16.00
{"stockData":{"symbol":"002370","market":"SZ","secType":"STK","nameCN":"亚太药业","latestPrice":5.75,"timestamp":1788850983000,"preClose":5.4,"halted":0,"volume":56272417,"delay":0,"changeRate":0.0648,"floatShares":746000000,"shares":746000000,"eps":-0.0125,"marketStatus":"已收盘","change":0.35,"latestTime":"09-08 15:00:00","open":5.39,"high":5.94,"low":5.36,"amount":324000000,"amplitude":0.1074,"askPrice":5.76,"askSize":4670,"bidPrice":5.75,"bidSize":296,"shortable":0,"etf":0,"ttmEps":-0.0125,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788917400000},"marketStatusCode":5,"adr":0,"adjPreClose":5.4,"symbolType":"stock","openAndCloseTimeList":[[1788831000000,1788838200000],[1788843600000,1788850800000]],"highLimit":5.94,"lowLimit":4.86,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":745667530,"isCdr":false,"pbRate":3.6,"roa":"--","roe":"--","epsLYR":0.13,"committee":-0.434562,"marketValue":4288000000,"turnoverRate":0.0755,"status":0,"floatMarketCap":4287000000},"requestUrl":"/m/hq/s/002370/","defaultTab":"news","newsList":[{"id":"2662750794","title":"亚太药业(002370)6月30日股东户数6.8万户，较上期减少22.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662750794","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662750794?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:42","pubTimestamp":1787737324,"startTime":"0","endTime":"0","summary":"证券之星消息，近日亚太药业披露，截至2026年6月30日公司股东户数为6.8万户，较3月31日减少2.01万户，减幅为22.86%。在化学制药行业个股中，亚太药业股东户数高于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.68万户。从股价来看，2026年3月31日至2026年6月30日，亚太药业区间跌幅为26.38%，在此期间股东户数减少2.01万户，减幅为22.86%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600039846.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","002370"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662976601","title":"亚太药业2026年半年报：扣非净利扭亏，经营现金流转负","url":"https://stock-news.laohu8.com/highlight/detail?id=2662976601","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662976601?lang=zh_cn&edition=full","pubTime":"2026-08-26 09:47","pubTimestamp":1787708852,"startTime":"0","endTime":"0","summary":"蓝鲸新闻8月26日讯，8月25日，亚太药业 公布2026年中报，公司依托医药制造主业，通过优化产品结构、强化费用管控及消除可转债利息支出影响，实现扣非净利润扭亏为盈；但受上年同期出售子公司产生大额投资收益的高基数影响，归母净利润同比大幅下滑，且经营活动现金流承压。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787707730529122227","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["SPHQ","BK0132","BK0239","BK4588","002370","BK4585","159399"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662751702","title":"图解亚太药业中报：第二季度单季净利润同比下降98.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662751702","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662751702?lang=zh_cn&edition=full","pubTime":"2026-08-26 03:23","pubTimestamp":1787685786,"startTime":"0","endTime":"0","summary":"证券之星消息，亚太药业2026年中报显示，上半年度公司主营收入1.58亿元，同比上升3.58%；归母净利润-43.55万元，同比下降100.41%；扣非净利润139.54万元，同比上升102.86%；其中2026年第二季度，公司单季度主营收入9794.62万元，同比上升11.91%；单季度归母净利润215.21万元，同比下降98.1%；单季度扣非净利润576.4万元，同比上升113.96%；负债率5.71%，投资收益111.76万元，财务费用-340.07万元，毛利率34.27%。财报数据概要请见下图:本文数据来源于亚太药业2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600005574.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662730715","title":"亚太药业扣非净利润同比增长102.86% 多维布局积蓄新动能","url":"https://stock-news.laohu8.com/highlight/detail?id=2662730715","media":"中国财富通","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662730715?lang=zh_cn&edition=full","pubTime":"2026-08-25 20:19","pubTimestamp":1787660386,"startTime":"0","endTime":"0","summary":"8月25日，亚太药业（002370）发布2026年半年报，上半年实现营收1.58亿元，同比增长3.58%；扣非净利润139.54万元，较上年同期实现扭亏为盈；财务费用同比降111%，非抗生素类高毛利产品占比升至56.71%。报告期内，亚太药业坚持\"仿创结合、创新驱动\"战略，搭建雅泰利众投资平台，前瞻布局光动力药物及配套器械、医药流通、医疗服务机器人等赛道，并通过参投基金的方式布局了创新药与眼科植入器械等领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=4xyckn4GBfU%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002370"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661231681","title":"股市必读：亚太药业新发布《关于与专业投资机构共同投资的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2661231681","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661231681?lang=zh_cn&edition=full","pubTime":"2026-08-21 02:31","pubTimestamp":1787250670,"startTime":"0","endTime":"0","summary":"截至2026年8月20日收盘，亚太药业报收于5.83元，上涨1.92%，换手率5.02%，成交量37.39万手，成交额2.21亿元。公司公告汇总关于与专业投资机构共同投资的进展公告浙江亚太药业股份有限公司全资子公司雅泰利众拟以自有资金出资500万元认购青岛阳和苍穹创业投资基金合伙企业的基金扩募份额，占其认缴出资总额的7.69%。该基金已完成工商变更登记，并在中国证券投资基金业协会完成私募投资基金变更备案，取得青岛市崂山区市场监督管理局核发的营业执照。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100001961.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","002370","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660422792","title":"股市必读：亚太药业新发布《关于与专业投资机构共同投资的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660422792","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660422792?lang=zh_cn&edition=full","pubTime":"2026-08-20 00:58","pubTimestamp":1787158690,"startTime":"0","endTime":"0","summary":"截至2026年8月19日收盘，亚太药业报收于5.72元，下跌5.3%，换手率5.45%，成交量40.63万手，成交额2.37亿元。公司公告汇总关于与专业投资机构共同投资的进展公告浙江亚太药业股份有限公司全资子公司雅泰利众拟以自有资金出资500万元认购青岛阳和苍穹创业投资基金合伙企业的基金扩募份额，占其认缴出资总额的7.69%。该基金已完成工商变更登记，并在中国证券投资基金业协会完成私募投资基金变更备案，取得青岛市崂山区市场监督管理局核发的营业执照。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000001409.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0132","002370"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659090107","title":"股市必读：亚太药业新发布《关于全资子公司参与认购投资基金份额的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2659090107","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659090107?lang=zh_cn&edition=full","pubTime":"2026-08-13 01:33","pubTimestamp":1786555990,"startTime":"0","endTime":"0","summary":"公司公告汇总：全资子公司拟出资500万元认购青岛阳和苍穹创业投资基金7.69%份额，投向高端制造等领域未上市及非公开交易股权资产。公司本次回购股份事项已实施完毕，本次回购符合相关法律法规的要求，符合公司既定的回购股份方案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300001113.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","002370"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658919583","title":"亚太药业（002370）披露全资子公司参与认购投资基金份额公告，8月11日股价上涨0.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658919583","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658919583?lang=zh_cn&edition=full","pubTime":"2026-08-11 22:27","pubTimestamp":1786458441,"startTime":"0","endTime":"0","summary":"截至2026年8月11日收盘，亚太药业报收于5.86元，较前一交易日上涨0.86%，最新总市值为43.7亿元。该股当日开盘5.84元，最高6.12元，最低5.82元，成交额达5.95亿元，换手率为13.34%。近日，亚太药业发布《关于全资子公司参与认购投资基金份额的公告》。公告显示，公司全资子公司浙江雅泰利众控股有限公司拟以自有资金出资500万元，认购青岛阳和苍穹创业投资基金合伙企业的基金份额，占其认缴出资总额的7.69%。公司本次投资存在收益不及预期或投资失败的风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100038435.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","002370","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658919342","title":"亚太药业：首次回购公司股份3344500股","url":"https://stock-news.laohu8.com/highlight/detail?id=2658919342","media":"证券日报网","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658919342?lang=zh_cn&edition=full","pubTime":"2026-08-11 21:32","pubTimestamp":1786455120,"startTime":"0","endTime":"0","summary":"证券日报网讯8月11日，亚太药业发布公告称，2026年8月11日，公司通过股份回购专用证券账户以集中竞价交易方式首次回购公司股份，本次回购股份3，344，500股，本次回购股份3，344，500股，占公司总股本的0.45%，最高成交价为6.03元/股，最低成交价为5.91元/股，成交总金额为19，998，005.00元人民币(不含交易费用)，本次回购股份事项已实施完毕。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-11/doc-inimyhkc7328313.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-11/doc-inimyhkc7328313.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002370","BK0132","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658941609","title":"异动快报：亚太药业（002370）8月10日9点38分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2658941609","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658941609?lang=zh_cn&edition=full","pubTime":"2026-08-10 09:45","pubTimestamp":1786326348,"startTime":"0","endTime":"0","summary":"证券之星8月10日盘中消息，9点38分亚太药业（002370）触及涨停板。其所属行业化学制药目前上涨。领涨股为哈药股份。该股为医药，化学原料药，新冠病毒防治概念热股，当日医药概念上涨1.24%，化学原料药概念上涨1.22%，新冠病毒防治概念上涨0.61%。8月7日的资金流向数据方面，主力资金净流入223.72万元，占总成交额1.2%，游资资金净流出675.27万元，占总成交额3.63%，散户资金净流入451.55万元，占总成交额2.43%。近5日资金流向一览见下表：亚太药业主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000003935.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","002370"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657068529","title":"股市必读：亚太药业新发布《关于回购公司股份的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657068529","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657068529?lang=zh_cn&edition=full","pubTime":"2026-08-06 01:09","pubTimestamp":1785949752,"startTime":"0","endTime":"0","summary":"回购股份报告书浙江亚太药业股份有限公司拟使用自有资金及股票回购专项贷款，以集中竞价交易方式回购公司股份，资金总额不低于1,000.00万元且不超过2,000.00万元，回购价格不超过7.00元/股；回购股份将用于实施股权激励或员工持股计划，回购期限为董事会审议通过之日起不超过12个月；公司已取得农业银行绍兴柯桥支行出具的1,800万元专项贷款承诺函；本次回购不会导致公司控制权变更，不影响上市地位及股权分布合规性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600001314.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","002370","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656355254","title":"亚太药业（002370）披露回购公司股份进展公告，8月4日股价上涨2.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656355254","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656355254?lang=zh_cn&edition=full","pubTime":"2026-08-04 22:19","pubTimestamp":1785853155,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘，亚太药业报收于5.05元，较前一交易日上涨2.43%，最新总市值为37.66亿元。近日，亚太药业披露《关于回购公司股份的进展公告》。公告显示，公司于2026年7月29日召开第八届董事会第十六次会议，审议通过了回购股份方案，拟使用自有资金及自筹资金以集中竞价交易方式回购公司股份，用于实施股权激励或员工持股计划。公司将根据市场情况推进回购计划，并及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400041418.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","002370","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656204583","title":"亚太药业：截至2025年末，在职员工人数较2024年末减少18人","url":"https://stock-news.laohu8.com/highlight/detail?id=2656204583","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656204583?lang=zh_cn&edition=full","pubTime":"2026-08-04 08:42","pubTimestamp":1785804130,"startTime":"0","endTime":"0","summary":"证券之星消息，亚太药业08月03日在投资者关系平台上答复投资者关心的问题。相比同行企业，贵公司2024—2025年员工人数和人均产出均呈下降趋势。截至2025年末，公司在职员工人数较2024年末减少18人，员工人数波动在正常范围内。未来，公司将继续围绕既定战略与业务需求合理配置人力资源，并按相关规定在定期报告中持续披露员工相关情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400007760.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0132","002370"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656277813","title":"亚太药业（002370）披露螺内酯片通过仿制药一致性评价公告，8月3日股价上涨1.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656277813","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656277813?lang=zh_cn&edition=full","pubTime":"2026-08-03 17:52","pubTimestamp":1785750774,"startTime":"0","endTime":"0","summary":"截至2026年8月3日收盘，亚太药业报收于4.93元，较前一交易日上涨1.65%，最新总市值为36.76亿元。该股当日开盘4.87元，最高4.94元，最低4.84元，成交额达6806.82万元，换手率为1.87%。近日，浙江亚太药业股份有限公司收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，公司螺内酯片通过仿制药质量和疗效一致性评价。药品生产与销售受政策、市场环境等因素影响，存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300025013.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370","BK0132","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656343379","title":"股市必读：亚太药业新发布《关于回购股份事项前十名股东和前十名无限售条件股东持股情况的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656343379","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656343379?lang=zh_cn&edition=full","pubTime":"2026-08-03 02:33","pubTimestamp":1785695592,"startTime":"0","endTime":"0","summary":"公司公告汇总：董事会于7月29日审议通过回购股份方案，并披露回购决议前一交易日的前十名股东及前十名无限售条件股东持股情况。前十名股东包括浙江星浩控股合伙企业、浙江星宸股权投资合伙企业等，持股数量和比例依次列示；前十名无限售条件股东持股情况与前十名股东一致。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300001015.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","002370","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655354261","title":"亚太药业（002370）披露回购股份事项前十名股东持股情况公告，7月31日股价上涨1.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655354261","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655354261?lang=zh_cn&edition=full","pubTime":"2026-07-31 17:43","pubTimestamp":1785491027,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，亚太药业报收于4.85元，较前一交易日上涨1.68%，最新总市值为36.16亿元。公告显示，浙江亚太药业股份有限公司于2026年7月29日召开第八届董事会第十六次会议，审议通过《关于回购股份方案的议案》。根据相关规定，公司现披露董事会公告回购股份决议前一交易日登记在册的前十名股东及前十名无限售条件股东持股情况。前十名无限售条件股东持股情况与前十名股东一致。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100029825.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","002370","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655220351","title":"亚太药业(002370.SZ)：螺内酯片通过仿制药质量和疗效一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2655220351","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655220351?lang=zh_cn&edition=full","pubTime":"2026-07-31 17:20","pubTimestamp":1785489635,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚太药业(002370.SZ)发布公告，公司于近日收到国家药品监督管理局核准签发的关于螺内酯片的《药品补充申请批准通知书》，公司螺内酯片通过仿制药质量和疗效一致性评价。螺内酯片适用于水肿性疾病、高血压、原发性醛固酮增多症及低钾血症的预防。本次螺内酯片通过仿制药质量和疗效一致性评价，将进一步丰富公司的产品管线，有利于提升该药品市场竞争力，同时为公司后续其他产品开展仿制药一致性评价工作积累经验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474656.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"亚太药业(002370.SZ)：螺内酯片通过仿制药质量和疗效一致性评价","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002370","BK0239","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655802241","title":"股市必读：亚太药业（002370）新发布《关于取得金融机构股票回购专项贷款承诺函的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2655802241","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655802241?lang=zh_cn&edition=full","pubTime":"2026-07-31 01:16","pubTimestamp":1785431813,"startTime":"0","endTime":"0","summary":"回购股份将用于实施股权激励或员工持股计划，回购期限为董事会审议通过之日起不超过12个月。关于回购股份事项前十名股东和前十名无限售条件股东持股情况的公告浙江亚太药业股份有限公司于2026年7月29日召开第八届董事会第十六次会议，审议通过《关于回购股份方案的议案》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100001130.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0132","002370"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655899300","title":"亚太药业（002370）披露取得金融机构股票回购专项贷款承诺函的公告，7月29日股价下跌0.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655899300","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655899300?lang=zh_cn&edition=full","pubTime":"2026-07-29 22:19","pubTimestamp":1785334751,"startTime":"0","endTime":"0","summary":"截至2026年7月29日收盘，亚太药业报收于4.77元，较前一交易日下跌0.21%，最新总市值为35.57亿元。该股当日开盘4.75元，最高4.83元，最低4.69元，成交额达8906.05万元，换手率为2.51%。近日，浙江亚太药业股份有限公司披露《关于取得金融机构股票回购专项贷款承诺函的公告》。公司近日取得中国农业银行绍兴柯桥支行出具的《贷款承诺函》，贷款额度1,800万元，期限3年，专门用于回购公司股票。公司将在回购期限内择机实施回购，并履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900040466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370","BK0239","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655656378","title":"亚太药业最新公告：拟以1000万元至2000万元回购公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2655656378","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655656378?lang=zh_cn&edition=full","pubTime":"2026-07-29 17:40","pubTimestamp":1785318001,"startTime":"0","endTime":"0","summary":"亚太药业(002370.SZ)公告称，公司拟以自有资金及自筹资金通过集中竞价交易方式回购公司部分股份，回购资金总额不低于1000万元(含)且不超过2000万元(含)，回购价格不超过7.00元/股。按回购金额上限测算，预计可回购约285.71万股，约占公司总股本的0.38%。回购股份将用于实施股权激励或员工持股计划，回购期限自董事会审议通过之日起不超过12个月。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900029480.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0132","002370"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788866126809,"stockEarnings":[{"period":"1week","weight":-0.0055},{"period":"1month","weight":0.0227},{"period":"3month","weight":-0.0092},{"period":"6month","weight":-0.1928},{"period":"1year","weight":-0.1628},{"period":"ytd","weight":-0.2613}],"compareEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":-0.0019},{"period":"3month","weight":-0.0193},{"period":"6month","weight":-0.0486},{"period":"1year","weight":0.0315},{"period":"ytd","weight":-0.0091}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江亚太药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"67959人(较上一季度减少22.86%)","perCapita":"10971股","listingDate":"2010-03-16","address":"浙江省绍兴市柯桥区群贤路2003号1501室","registeredCapital":"74566万元","survey":" 浙江亚太药业股份有限公司的主营业务是医药制造业务，包括化学制剂的研发、生产和销售。公司的主要产品是抗生素类制剂、非抗生素类制剂。公司拥有省级企业技术中心。","listedPrice":16},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚太药业(002370)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚太药业(002370)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚太药业,002370,亚太药业股票,亚太药业股票老虎,亚太药业股票老虎国际,亚太药业行情,亚太药业股票行情,亚太药业股价,亚太药业股市,亚太药业股票价格,亚太药业股票交易,亚太药业股票购买,亚太药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚太药业(002370)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚太药业(002370)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}